Regenxbio Sets May 14 Webcast to Unveil RGX-202 Trial Results and Q1 Financials
Regenxbio will host a May 14 webcast at 8:00 a.m. ET to discuss topline results from the pivotal RGX-202 gene therapy trial in Duchenne muscular dystrophy. The company will also release first-quarter 2026 financial results and operational highlights pre-market on the same day.
1. May 14 Webcast on RGX-202 Trial
Regenxbio will host a live webcast on May 14 at 8:00 a.m. ET to present topline results from its pivotal RGX-202 gene therapy trial in Duchenne muscular dystrophy, featuring commentary from Drs. Aravindhan Veerapandiyan, Carolina Tesi-Rocha and Diana Castro.
2. First-Quarter 2026 Financial Release
The company plans to release its first-quarter 2026 financial results and operational highlights pre-market on May 14, detailing revenue performance, research expenditures, and development milestones across its portfolio.
3. RGX-202 and Clinical Pipeline
RGX-202 uses an AAV-based platform to deliver functional dystrophin expression in Duchenne patients and represents a key asset in Regenxbio’s late-stage pipeline alongside RGX-121 for MPS II, RGX-111 for MPS I and ABBV-RGX-314 for retinal diseases.